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Abstract
Background/Objectives
Antibiotic use in early life has been associated with weight gain in several populations. How-
ever, associations between chronic antibiotic use and weight among adults in the general
population are unknown.
Subjects/Methods
The NIEHS Sister Study is a longitudinal cohort of sisters of women with breast cancer. We
examined associations between chronic antibiotic use (� 3 months) during the fourth decade
of life (30–39 years) and subsequent obesity at enrollment (mean age = 55) via logistic
regression. We also examined associations between chronic antibiotic use in the 5 years and
12 months prior to enrollment and weight gain after enrollment in linear mixed models. Mod-
els were adjusted for race/ethnicity, education, urban/rural status, age, and smoking.
Results
In adjusted analyses (n = 50,237), chronic penicillin use during the 4th decade of life was
associated with obesity at enrollment (OR 2.00, 95% CI 1.40, 2.87), and use in the 5 years
prior to enrollment was associated with increased BMI change after enrollment (β 1.00 95%
CI 0.01, 2.00). Use of bactericidals (OR 1.71, 95% CI 1.29, 2.26) during the 4th decade of
life was also associated with obesity at enrollment. Associations for penicillins and bacterici-
dals were consistent across indications for use. Bacteriostatic use in the 5 years prior to
enrollment was associated with a reduction in BMI after enrollment (β -0.52, 95% CI -1.04,
0.00), and tetracycline use during the 4th decade of life was associated with reduced odds of
obesity at enrollment (OR 0.72, 95% CI 0.56, 0.92). However, these inverse associations
were only present for those who reported taking antibiotics for skin purposes. Cephalospo-
rins, macrolides, quinolones, and sulfonamides were not associated with BMI change over
time.
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Conclusions
Chronic use of antibiotics during adulthood may have long-lasting impacts on BMI. Associa-
tions may differ by antibiotic class, and confounding by indication may be important for
some antibiotic classes.
Introduction
Antibiotics have been used for growth promotion in several species of livestock since the 1950s
[1, 2], although the hypothesis that antibiotic use may similarly result in weight gain in healthy
humans has only recently been investigated. Oral antibiotics increase height and weight of
children with malnutrition or infection in low and middle income countries (reviewed in [3]).
Antibiotic treatment of severe, chronic diseases in adults has also been associated with weight
gain. Macrolide treatment for cystic fibrosis [4]; omeprazole, amoxicillin, and clarithromycin
combination treatment for Helicobacter pylori [5]; and treatment of infective endocarditis with
vancomycin and gentamycin [6]; were all associated with increased weight gain in treated
patients. These weight gain effects may have been mediated by the treatment of infectious dis-
ease, since infections may lead to reduced absorption of nutrients, increased loss of nutrients
from diarrhea, nutrient diversion from growth to immune support, and lack of appetite [7–9].
Other evidence supports a microbiome-mediated pathway for the relationship between
antibiotics and obesity. Chronic and repeated antibiotic and probiotic use may have a pro-
found impact on the composition of the gut microbiome [10–12], which differs between obese
and lean people [13–15]. In animal and human studies, some probiotic strains have been asso-
ciated with weight gain (reviewed in [16]), though others have shown associations with weight
loss [17–19]. Since probiotics do not treat infections, at least some of the mechanism by which
probiotics cause weight gain may be via alteration of gut microbiota and not via a protective
effect against harmful pathogens. Transplanting fecal microbiota from lean/obese discordant
human twin pairs into germfree mice led to weight gain in the mice that received the micro-
biota from the obese twins [20], implying that the microbiota themselves may be responsible
for weight alteration.
Bacteria may influence the host’s weight via several mechanisms. Bacteria are responsible
for the metabolism of complex carbohydrates that result in short chain fatty acids [21], which
provide an additional source of energy for the body through lipid and glucose synthesis and
absorption of monosaccharides from the gut lumen [22]. This absorption induces hepatic lipo-
genesis, is responsible for depositing triglycerides in fat cells, and generally influences energy
harvest from the diet and storage of energy in the host [23].
In humans, there has been a recent explosion of epidemiological evidence supporting an
association between early-life antibiotics and overweight and obesity in children [24–33],
although indication for use may be an important confounder [32]. As the first year of life is
critical for development of the microbiota, this research suggests that disruption of the devel-
opment of the microbiome during infancy may lead to increased BMI in later life, and the
effect may vary by type of antibiotic. However, because microbiota are responsible for energy
harvesting and storage throughout life, and because even week-long doses of antibiotics may
alter microbial composition for 2 years in adults [34], chronic antibiotic exposure in adulthood
may also result in altered weight. This has not been previously explored from a chronic disease
perspective, in part because long-term antibiotic use is somewhat rare. To address this gap, we
conducted an analysis to examine the association of different antibiotics with weight and
weight change in a large prospective cohort of adult women.
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Methods
Study population
The National Institute of Environmental Health Sciences Sister Study is a prospective cohort
study of environmental and genetic risk factors for breast cancer and other endpoints in
approximately 50,000 women ages 35 to 74 years [35]. At enrollment, participants were unaf-
fected with breast cancer but did have a sister who was diagnosed with the disease. Women
were recruited from all 50 states in the USA and Puerto Rico. Although they are similar to the
general population with regard to some lifestyle factors, as with most volunteer cohorts, partic-
ipants tend to be healthier and to have higher socioeconomic status than similarly aged
women from the general population. We used data from Sister Study Data Release 4.1, which
contains baseline data and two detailed follow-ups that include height and weight. Details of
the study have been described elsewhere. For this study, all women who were not currently
pregnant or breastfeeding with complete data on anthropometry at enrollment and anthropo-
metric history, history of antibiotic usage, and covariates were included in analyses. This
research was approved by the Institutional Review Boards of the National Institute of Environ-
mental Health Sciences, NIH, and the Copernicus Group.
Anthropometric measurement
At enrollment (ages 35–74, mean age = 55), examiners visited participant’s homes and mea-
sured height and weight. On the enrollment questionnaire, women reported height and weight
during their 30’s. Additionally, at the first and second detailed follow-ups, women self-
reported current height and weight. Body mass index (BMI) was calculated using the formula
weight (lb)/ [height(in)]2 x703, and we used the CDC adult conventions to determine weight
status [36]. BMI below 18.5 is considered underweight, 18.5 to<25.0 is normal weight, 25.0 to
<30 is overweight, and 30.0 and above is obese.
Percent changes in BMI were also calculated for changes from a woman’s 30s (4th decade of
life) to enrollment, from enrollment to the first detailed follow-up, from enrollment to the sec-
ond detailed follow-up, and from the first to the second detailed follow-up. At enrollment, we
used BMI from the examiner-measured height and weight data, and at all other instances used
the self-report. In sensitivity analyses, we evaluated self-reported BMI at enrollment.
Antibiotic use
At enrollment, women reported whether they had ever taken oral antibiotics at least three
times a week for three months or longer, excluding topical antibiotics. They additionally
reported the name of the antibiotic, the indication for use, the age they first started taking the
antibiotic regularly, and the duration of use.
We collapsed antibiotics into classes for analyses, including aminoglycosides, cephalospo-
rins, chloramphenicol, macrolides, penicillins, other beta lactams, quinolones, sulfonamides,
tetracyclines, and other antibiotics. We also grouped antibiotics by whether they are bacteri-
cidal (penicillins, quinolones, cephalosporins, aminoglycosides, other beta-lactams) or bacteri-
ostatic (tetracyclines, macrolides, sulfonamides, chloramphenicol). We collapsed indications
into categories of skin issues (i.e. rosacea, acne), and non-skin issues (ear nose and throat,
respiratory, prevention [taking prior to surgery or dental visits], sinus, urinary tract infections,
other), since this categorization was the best predictor of weight change. In analyses of individ-
ual antibiotics, we considered binary variables indicating ever-use of antibiotic classes with at
least 20 exposed participants, thus, we excluded aminoglycosides (n = 13), chloramphenicols
(n = 5), and other beta lactams (n = 2). We also considered antibiotic use during a woman’s
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30s, antibiotic use in the year prior to enrollment, and antibiotic use in the five years preceding
enrollment.
Covariates
To identify important covariates for estimating the relationship between chronic antibiotic use
and weight gain, we considered a directed acyclic graph (DAG) to identify possible confound-
ers, colliders, and mediators [37]. Variables in the DAG included race/ethnicity, education,
age at enrollment, urban/rural status, smoking, exercise, diabetes, sugary beverage intake at
enrollment, total calorie intake at enrollment, and healthy lifestyle. All models were adjusted
for race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), education
(binary variable indicating at least bachelor’s degree), age at enrollment (four categories
included <45, 45 to<55, 55 to<65, and over 65), urban/rural status (binary variable indicat-
ing urban residence at enrollment), and smoking status (total pack years, calculated from
packs/day � years smoked). Distributions of these variables were calculated for the populations
at enrollment and at each follow-up. We also calculated the length of time participants
reported using each antibiotic class, and report the medians and the 25th and 75th percentiles
for each class. These measures are included only for those who report using antibiotics.
Data analysis
We estimated prevalence odds ratios of the associations between ever use of antibiotics and
obesity at enrollment in logistic regression models. We also estimated associations between
use of antibiotics during the 30s and obesity at enrollment (minimum age at enrollment = 35,
mean age = 55). To assess this, we considered those who initiated antibiotic use during their
30s as exposed. Those who initiated antibiotic use outside of that timeframe were excluded.
This approach addressed the concern that initiation of antibiotic use prior to their 30s might
capture weight gain prior to their 30s. It also addressed the concern that initiation of antibiotic
use after the 4th decade of life might not represent a model where the exposure precedes weight
gain, and also narrows the time window between last reported weight and initiation of antibi-
otic use. We also estimated associations between use of antibiotics during their 30s and obesity
at enrollment in a logistic regression model that excluded women with obesity during their
30s.
We also took advantage of more recently collected data to minimize recall bias of weight
and antibiotic use. We estimated associations between reported antibiotic use in the 12 months
prior to enrollment, and five years prior to enrollment, and percent changes in BMI from
enrollment to each follow up and from the 1st to the 2nd follow up. We used a linear mixed
regression model with random effects for subject, fixed effects for the covariates listed previ-
ously, and unstructured covariance to perform longitudinal analyses. In addition to control-
ling for the standard set of covariates, we controlled for BMI at enrollment. In sensitivity
analyses, we omitted this variable. Since several participants reported using multiple antibiotic
classes, and since users of other antibiotics were included in the referent categories for several
models, we also performed sensitivity analyses where the exposed category included only those
who reported using the antibiotic class of interest, and the referent category only included
those who reported no antibiotic use. Participants who reported using other antibiotic classes
were excluded from these models.
To account for possible confounding by indication, we separately considered associations
between antibiotics taken for skin and antibiotics taken for non-skin purposes in modeling
antibiotic associations with weight gain. Women who did not use antibiotics were not asked
about these conditions or, if asked, asked in the same way as women who used antibiotics, and
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therefore we were unable to assess interactions between antibiotics and indications. Instead,
we compared associations for antibiotic users who reported uses for skin, and users who
reported uses for non-skin, and compared those against participants who did not report using
that antibiotic.
We conducted several sensitivity analyses. These included evaluating modification by race/
ethnicity, and diabetes status, at an alpha of 0.10. We controlled for time between first and sec-
ond follow ups in longitudinal models, and also separately evaluated whether associations
between antibiotic use differed by age at initiation. To assess this, we examined childhood ini-
tiation (<15 years), early adult initiation (15–45), and menopause initiation (45–55), and asso-
ciations with obesity at enrollment, restricted to participants who were over the age of 55.
All statistical analyses were performed in R V3.3.1.
Results
Women in the Sister Study were predominantly white, between 40 and 60 years of age at
enrollment, of normal weight, and approximately half had a college degree (Table 1). Of
50,884 women who were enrolled, 50,237 had complete covariate, exposure, and weight data
and met inclusion criteria. Of the included women, 46,697 (93%) completed the first follow-up
and 44,381 (88%) completed the second follow-up. Demographic composition was stable over
follow-up (Table 1). The first and second follow-ups took place on average 2.8 (sd = 0.6) and
5.7 (sd = 1.0 years) years after enrollment, respectively. The median length of use was 12
months for macrolides, penicillins, and sulfonamides, 6 months for cephalosporins and quino-
lones, and 24 months for tetracyclines (Table 1).
In adjusted analyses of the associations between ever-use of antibiotics and obesity at
enrollment, ever-use of cephalosporins (OR 1.78, 95% CI 1.38, 2.29), penicillins (OR 1.35, 95%
CI 1.20, 1.52), quinolones (OR 1.69, 95% CI 1.37, 2.09), and bactericidal antibiotics (OR 1.43,
95% CI 1.29, 1.58) were associated with an increased odds of obesity at enrollment (Table 2).
Ever-use of tetracyclines (OR 0.76, 95% CI 0.70, 0.83) and bacteriostatic antibiotics (OR 0.84,
95% CI 0.78, 0.91) were associated with a lower odds of obesity (Table 2). Macrolides and sul-
fonamides showed no association between ever-use and obesity at enrollment. Similarly, ever
use of any antibiotic was not associated with obesity at enrollment. Similar associations were
evident at the 1st and 2nd follow-ups, and for both adjusted and unadjusted ORs.
Associations between antibiotic use during the 4th decade of life (30s) and obesity at enroll-
ment resulted in slightly different findings. Use of penicillins (OR 2.00, 95% CI 1.40, 2.87) and
bactericidals (OR 1.71, 95% CI 1.29, 2.26), but not cephalosporins, quinolones or the broad
“any antibiotic” category, during their 30s was associated with obesity at enrollment (Table 3).
Initiating use of tetracyclines (OR 0.72, 95% CI 0.56, 0.92), or any bacteriostatic antibiotic (OR
0.82, 95% CI 0.67, 1.01), during a woman’s 30s was inversely associated with obesity (Table 3).
The magnitudes of the associations for penicillins and bactericidals were similar across catego-
ries of indications for use (Table 4). The OR for skin was non-significant for penicillins and
bactericidals, but few participants reported use of these antibiotics for skin conditions (n = 21
for penicillins, n = 30 for bactericidals). The inverse association between tetracyclines and obe-
sity was only present for skin-users (OR 0.64, 95% CI 0.48, 0.85); the OR for non-skin condi-
tion use was 1.19, 95% 0.70, 2.02. Similarly, the inverse association between bacteriostatic use
and obesity was only seen for skin users.
Findings for penicillin were similar when we examined associations between reported anti-
biotic use immediately prior to enrollment and weight gain during the follow-up periods
(Table 5). Penicillin use in the 5 years prior to enrollment was associated with increased weight
gain (% change in BMI) after follow-up (β 1.00, 95% CI 0.01, 2.00). Although the beta estimate
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for penicillin use in the 12 months prior to enrollment was similarly elevated, the association
was not significant (β 1.53, 95% CI -025, 3.31). These effect sizes are relatively modest; using
penicillin in the past 5 years was associated with a 1% gain in BMI. For example, for a 5’5”
woman who weighed 150 pounds at enrollment, this represents a gain of approximately 1.5–2
pounds over the entire follow-up period. Conversely, bacteriostatic use in the 5 years prior to
enrollment was associated with weight loss over follow-up (β -0.52, 95% CI -1.04, 0.00),
although there was no significant association for bacteriostatic use 12 months prior to enroll-
ment (β 0.28, 95% CI -0.67, 1.22). In contrast to results from models examining use in earlier
life (initiation of use in 30s), examining use in the 12 months or 5 years prior to enrollment
resulted in no consistent association between tetracyclines or bactericidals and weight change
after enrollment. For all models, associations were unchanged in sensitivity analyses where the
exposed category included only those who reported using the antibiotic of interest, and the ref-
erent category included only those who reported never taking any antibiotics.
Sensitivity analyses included assessing modification by race/ethnicity and diabetes status,
confounding by time between first second follow-ups, and age at antibiotic initiation. None of
these analyses influenced associations or changed interpretations.
Table 1. Characteristics of study population by follow-up.
Characteristic Total Population at Enrollment 1st Follow-up 2nd Follow-up
N = 50,237 N = 46,697 N = 44,381
Continuous Variables (Mean (SD))
BMI in 30s 23.30 (3.99) 23.24 (3.94) 23.19 (3.84)
Smoking in pack years 6.40 (12.48) 6.28 (12.33) 6.22 (12.21)
Current Smoking (Any) n (%) 4,056 (8.07) 3,565 (7.63) 3,285 (7.40)
Categorical Variables (n (%))
Education No College 24,615 (49.00) 22,539 (48.27) 21,103 (47.54)
College Degree 25,622 (51.00) 24,158 (51.73) 23,278 (52.46)
Race/
Ethnicity
NH white 42,073 (83.75) 39,579 (84.76) 38,436 (86.60)
NH Black 4,345 (8.71) 3,779 (8.09) 3,070 (6.91)
Hispanic 2,477 (4.93) 2,149 (4.60) 1,738 (3.92)
Other 1,313 (2.61) 1,190 (2.55) 1,137 (2.56)
Urban Rural 21,099 (41.98) 19,671 (42.12) 18,753 (42.25)
Urban 29,162 (58.02) 27,026 (57.88) 25,628 (57.75)
Age at Enrollment 35–44 6,461 (12.87) 5,856 (12.54) 5,478 (12.34)
45–54 17,330 (34.50) 15,990 (34.24) 15,216 (34.28)
55–64 17,712 (35.26) 16,672 (35.70) 15,923 (35.88)
� 65 8,734 (17.39) 8,179 (17.51) 7,764 (17.49)
Ever Chronic Antibiotic Use None 44,977 (89.53) 41,785 (89.48) 39,694 (89.37)
Any 5,260 (10.47) 4,912 (10.52) 4,720 (10.63)
Length of Antibiotic Use� (Median, 25/75 percentile in months) Cephalosporins 6 (3, 12) 6 (3, 12) 6 (3, 12)
Macrolides 12 (6, 30) 12 (6, 24) 12 (6, 24)
Penicillins 12 (4, 36) 12 (4, 36) 12 (4, 36)
Quinolones 6 (3, 12) 6 (3, 12) 6 (3, 12)
Sulfonamides 12 (6, 36) 12 (6, 36) 12 (6, 36)
Tetracyclines 24 (12, 36) 24 (12, 36) 24 (12, 36)
Total population at enrollment includes participants at enrollment who met inclusion criteria for the current study, 1st follow-up includes participants who returned the
1st follow-up questionnaire and had BMI information, 2nd follow-up includes participants who returned the 2nd follow-up questionnaire and had BMI data.
�Medians and 25/75 percentiles for antibiotic use are calculated based only on those who reported ever using that specific class
https://doi.org/10.1371/journal.pone.0216959.t001
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Discussion
Across all analyses, penicillin use was prospectively associated with weight gain or obesity,
which appeared independent of indication for use. Although bactericidal use during the 4th
decade of life was associated with obesity at enrollment, the association between bactericidal
use immediately prior to enrollment and subsequent weight gain was not significant. Although
use of tetracyclines and bacteriostatics were associated with reduced odds of obesity among
those taking antibiotics for skin purposes, there was no association for participants taking
these antibiotics for non-skin purposes. Additionally, most bacteriostatics users were tetracy-
clines users, and this association was likely driven by tetracyclines. Finally, ever-use of cephalo-
sporins, quinolones, penicillins and bactericidals were cross-sectionally associated with obesity
at enrollment, although cephalosporins and quinolones were not associated with weight gain
in prospective analyses that minimized the possibility of reverse causality. Reverse causality is
not a trivial concern, since the obese population has a higher risk of infection than the non-
obese population [38].
The association between antibiotics and weight change is biologically plausible and poten-
tially mediated by changes in the gut microbiota and alterations in hormones that regulate
energy homeostasis, such as leptin and ghrelin [23]. Antibiotic exposure does alter the compo-
sition of microbial communities (reviewed in [34]). However, there is a wide range of micro-
bial action across antibiotic classes and antibiotic targets. Tetracyclines and bacteriostatics
were paradoxically associated with reduced weight, although only among those using tetracy-
clines for skin conditions. This suggests the possibility of confounding by indication for these
classes of antibiotics. Although associations between penicillins and bactericidals were
Table 2. Prevalence odds ratios of associations between antibiotic use and obesity.
At Enrollment
N = 50,237
At 1st Follow-up
N = 46,697
At 2nd Follow-up
N = 44,381
�Not Obese Obese Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)1
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)1
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)1
No Cephalosporins 35,114 14,872 1.78 (1.39, 2.29) 1.78 (1.38, 2.29) 1.54 (1.18, 2.01) 1.53 (1.17, 2.00) 1.57 (1.20, 2.07) 1.58 (1.20, 2.08)
Ever Cephalosporin 143 108
No Macrolides 34,780 14,788 0.95 (0.80, 1.12) 1.03 (0.87, 1.22) 1.08 (0.91, 1.28) 1.15 (0.97, 1.37) 1.10 (0.92, 1.30) 1.15 (0.97, 1.37)
Ever Macrolides 477 192
No Penicillins 34,479 14,512 1.43 (1.27, 1.61) 1.35 (1.20, 1.52) 1.35 (1.19, 1.53) 1.27 (1.12, 1.44) 1.29 (1.14, 1.47) 1.21 (1.06, 1.38)
Ever Penicillins 778 468
No Quinolones 35,050 14,825 1.77 (1.44, 2.18) 1.69 (1.37, 2.09) 1.50 (1.19, 1.88) 1.44 (1.14, 1.81) 1.27 (0.99, 1.62) 1.21 (0.94, 1.55)
Ever Quinolones 207 155
No Sulfonamides 34,915 14,833 1.01 (0.83, 1.23) 1.03 (0.84, 1.25) 1.07 (0.88, 1.31) 1.09 (0.89, 1.34) 1.14 (0.93, 1.39) 1.16 (0.94, 1.42)
Any Sulfonamides 342 147
No Tetracyclines 32,848 14,262 0.69 (0.63, 0.75) 0.76 (0.70, 0.83) 0.71 (0.65, 0.77) 0.77 (0.71, 0.85) 0.75 (0.68, 0.82) 0.81 (0.74, 0.89)
Ever Tetracyclines 2,409 718
No Antibiotics 31,494 13,483 0.93 (0.87, 0.99) 0.98 (0.92, 1.05) 0.92 (0.86, 0.98) 0.96 (0.89, 1.02) 0.94 (0.88, 1.00) 0.97 (0.91, 1.04)
Ever Any Antibiotic 3,763 1,497
No Bactericidals 34,207 14,007 1.50 (1.36, 1.65) 1.43 (1.29, 1.58) 1.39 (1.25, 1.54) 1.32 (1.18, 1.47) 1.33 (1.19, 1.49) 1.26 (1.13, 1.41)
Ever Bactericidal 1,050 658
No Bacteriostatics 32,323 14,007 0.77 (0.71, 0.83) 0.84 (0.78, 0.91) 0.79 (0.73, 0.85) 0.85 (0.79, 0.92) 0.83 (0.77, 0.90) 0.89 (0.82, 0.96)
Ever Bacteriostatics 2,934 973
�Obese case numbers reflect obesity status at enrollment. N’s for each time point reflect those with complete covariate and outcome data.
1Covariates for adjusted models include race/ethnicity, education, urban/rural, age, and total smoking pack years
https://doi.org/10.1371/journal.pone.0216959.t002
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consistent across indications, the number of participants who reported using these antibiotics
for skin conditions was relatively small. Prior research has also suggested that infections, and
not antibiotics, drive obesity [32]. Although this possibility cannot be ruled out in our study, if
this were true we would expect to see an overall effect for antibiotic use and obesity in our pop-
ulation, across antibiotic classes. However, we only report a consistent association for penicil-
lins, which argues against this potential confounder. Alternatively, if penicillins tend to be
prescribed more after intestinal surgery in response to longer and more resistant infections,
compared to other antibiotics, this may be another possible confounding factor. Possible
explanation for the differences may be due to differences in targeted action; for instance, later
generations of penicillins are generally considered to be broad-spectrum antibiotics. Research-
ers have speculated that broad-spectrum and narrow-spectrum antibiotics may differentially
alter bacterial diversity in humans [39]. Interestingly, tetracyclines are also considered broad-
spectrum antibiotics, and these classes generally had opposite effects on obesity. It is plausible
that broad-spectrum antibiotics may be more likely to influence weight changes through
broad alterations in the microbiome, and the direction of this weight change (up or down)
may be a function of the specific antibiotic class.
Differing results from the cross-sectional analyses and longitudinal analyses could be due to
a few factors. First, people who are overweight or obese are more likely to acquire an infection
[38] and thus need antibiotics. These individuals may also be less likely to engage in physical
activity due to their health status. Any cross-sectional analysis of a population that reports
associations between antibiotics and obesity will capture some of this phenomenon. Second,
the populations in the cross-sectional and longitudinal analyses are different. The cross-
Table 3. Incidence odds ratios of associations for initiating antibiotic use during the 4th decade of life with obesity
at enrollment.
1Not Obese Obese Adjusted
OR (95% CI)2
No Cephalosporins1 34,659 11,898 1.52 (0.90, 2.55)
Ever Cephalosporin 44 22
No Macrolides 34,326 11,832 1.01 (0.65, 1.55)
Ever Macrolides 93 28
No Penicillins 34,044 11,620 2.00 (1.40, 2.87)
Ever Penicillins 77 52
No Quinolones 34,595 11,853 1.02 (0.50, 2.09)
Ever Quinolones 34 10
No Sulfonamides 34,462 11,853 1.11 (0.68, 1.81)
Any Sulfonamides 63 22
No Tetracyclines 32,411 11,412 0.72 (0.56, 0.92)
Ever Tetracyclines 342 77
No Antibiotics 31,269 10,851 1.01 (0.85, 1.19)
Ever Any Antibiotic 594 189
No Bactericidals 33,775 11,464 1.71 (1.29, 2.26)
Ever Bactericidal 144 80
No Bacteriostatics 31,891 11,197 0.82 (0.67, 1.01)
Ever Bacteriostatics 470 120
1Use reflects initiation of chronic antibiotic use during the 4th decade of life (30s). Models exclude women who
reported being obese during their 30’s
2All models adjusted for race/ethnicity, education, urban/rural, age, and total smoking pack years.
https://doi.org/10.1371/journal.pone.0216959.t003
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sectional analyses classify everyone who ever chronically used an antibiotic as exposed, while
the longitudinal analyses classifies only those who used antibiotics in their 30s, or those who
used antibiotics in the 12 or 60 months prior to enrolling in the Sister Study, as exposed. Anti-
biotic use at different time points in life may have varying effects–puberty, pregnancy, and
menopause are all hormonally driven events that might modify any effects of antibiotics on
weight gain. These time periods, with the exception of pregnancy, were mostly excluded from
the prospective analyses, but included in cross-sectional analyses. Additionally, analyses that
predict weight gain after enrollment based on pre-enrollment antibiotic use will fail to capture
many of those who experienced weight gain immediately after antibiotic use, biasing those
results towards the null. These effects would, however, be captured in the cross-sectional
analyses.
In general, previous studies of antibiotic use during infancy and overweight and obesity in
children’s cohorts have implicated exposure to multiple classes of antibiotics rather than peni-
cillins alone [26, 27, 33]. However, one study reported adverse associations with penicillins,
cephalosporins, and macrolides [25], and a randomized clinical study in adults reported
weight gain in patients treated for H. pylori with amoxicillin [5]. Another cohort reported no
Table 4. Associations between antibiotic use1 during the 4th decade of life and obesity at enrollment, according to
indications for use3.
N Not obese/Obese OR2 (95% CI)
Macrolides
No Macrolide Use 34,326 / 11,832 Ref
Macrolides for Skin 56/15 0.97 (0.54, 2.1.73)
Macrolides for Non-Skin 37/13 1.06 (0.56, 2.01)
Penicillins
No Penicillin Use 34,044 / 11,620 Ref
Penicillins for Skin 13/8 2.32 (0.94, 5.73)
Penicillins for Non-Skin 64/44 1.95 (1.32, 2.88)
Sulfonamides
No Sulfonamide Use 34,462/ 11,853 Ref
Sulfonamides for Skin 16/3 0.69 (0.20, 2.39)
Sulfonamides for Non-Skin 47/19 1.23 (0.72, 2.11)
Tetracyclines
No Tetracycline Use 32,411 / 11,412 Ref
Tetracyclines for Skin 290/58 0.64 (0.48, 0.85)
Tetracyclines for Non-Skin 52/19 1.19 (0.70, 2.02)
Bactericidals
No Bactericidal Use 33,775/ 11,464 Ref
Bactericidals for Skin 19/11 2.16 (1.01, 4.61)
Bactericidals for Non-Skin 125/69 1.65 (1.22, 2.23)
Bacteriostatics
No Bacteriostatic Use 31,891 / 11,197 Ref
Bacteriostatics for Skin 342/73 0.70 (0.54, 0.90)
Bacteriostatics for Non-Skin 128/47 1.12 (0.0.80, 1.57)
1Use reflects initiation of chronic antibiotic use during the 4th decade of life (30s). Models exclude women who
reported being obese during their 30’s
2All models adjusted for race/ethnicity, education, urban/rural, age, and total smoking pack years
3Cephalosporins and quinolones had fewer than 10 reported users for skin and are excluded
https://doi.org/10.1371/journal.pone.0216959.t004
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effect for penicillins (a narrow spectrum antibiotic) but did report effects for broad-spectrum
antibiotics [27]. Infancy presents a very different microbial developmental window, and differ-
ent antibiotics may have differing impacts on the microbiota of infants relative to adults. Addi-
tionally, others included short-term use of antibiotics while we examined longer-term, chronic
use. Differences in effects of broad and narrow spectrum antibiotics are not consistent across
prior cohort studies. While penicillins can be reliably classified as narrow spectrum, other
antibiotic classes differ in their targets by generation and we were unable to reliably classify
antibiotics by targeted spectrum. Classification of bacteria as having bactericidal (kills bacterial
cells) or bacteriostatic (inhibits growth of bacterial cells) action has been used previously in
examining associations with diabetes [40, 41], although the distinction has not previously been
adopted in studies of associations with obesity or weight gain.
There were several strengths and limitations to this study. Primary limitations include the
lack of indications data among non-antibiotic users, the lack of data about shorter-term antibi-
otic use (e.g., 7–10 days of antibiotics at a time), the entirely female and mostly white makeup
of the study population, and the relatively small numbers of long-term users of antibiotics. We
were unable to perform a true analysis of the interaction between illness and antibiotics, as we
had no data on the relevant illnesses in non-antibiotic users. For instance, if someone reported
no antibiotic use, they were not asked about possible antibiotic-related illnesses. Thus, we did
not know if non-users had a skin condition or a respiratory condition, and could not evaluate
the effect of antibiotics among all participants with a particular condition. Instead, we were
Table 5. Mixed models of longitudinal associations between antibiotic use before enrollment and percentage
change in body mass index between follow-ups.
Antibiotic use 12 months Prior To
Enrollment
β (95% CI)
Antibiotic Use 5 years Prior To
Enrollment
β (95% CI)
Cephalosporins N Use/No
Use
26/48,099 72/48,053
Cephalosporins β (95% CI) 0.06 (-2.31, 2.42) -0.21 (-1.63, 1.20)
Macrolides N Use/No Use 25/48,080 99/48,006
Macrolides β (95% CI) -0.55 (-2.94, 1.84) -0.92 (-2.12, 0.28)
Penicillins N Use/No Use 48/48,046 152/47,942
Penicillins β (95% CI) 1.53 (-0.25, 3.31) 1.00 (0.01, 2.00)
Quinolones N Use/No Use 33/48,087 165/47,955
Quinolones β (95% CI) -1.18 (-3.29, 0.94) -0.52 (-1.46, 0.42)
Sulfonamides N Use/No
Use
19/48,095 83/48,031
Sulfonamides β (95% CI) -1.61 (-4.50, 1.27) -0.60 (-1.92, 0.72)
Tetracyclines N Use/No Use 121/47,970 271/47,720
Tetracyclines β (95% CI) 0.80 (-0.29, 1.90) -0.43 (-1.05, 0.20)
Bactericidals N Use/No Use 103/48,031 366/47,768
Bactericidals β (95% CI) 0.71 (-0.50, 1.91) 0.04 (-0.60, 0.67)
Bacteriostatics N Use/No
Use
163/47,971 534/47,600
Bacteriostatics β (95% CI) 0.28 (-0.67, 1.22) -0.52 (-1.04, 0.00)
Linear Regression with random effects for subject and visit. BMI reported at enrollment, at first follow-up, and
second follow-up. Percent change in BMI calculated for time between enrollment and first follow-up, time between
first follow-up and second follow-up, and time between enrollment and second follow-up. All models adjusted for
race/ethnicity, education, urban/rural, age, smoking, and BMI at enrollment. Results are similar without controlling
for BMI at enrollment.
https://doi.org/10.1371/journal.pone.0216959.t005
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limited to estimating associations for participants who used antibiotics for skin purposes, used
for non-skin purposes, or did not use that antibiotic. The confidence intervals for most of
these associations were quite wide, which limited any assessment of whether the effects were
different by indication category. However, we can generally conclude that the associations for
penicillins remained consistent regardless of indication, while associations for tetracyclines/
bacteriostatics seemed to vary by indication.
Another variable with potential misclassification is self-reported weight, particularly during
the participant’s 30’s. Weight may fluctuate significantly over a decade, and it is unknown
whether women reported average weight, maximum weight, or minimum weight during their
30s. However, BMI in 30s was similar for antibiotic and non-antibiotics users, suggesting that
outcome misclassification is likely non-differential by exposure status. Additionally, we used
self-reported weight at both follow-ups, which may be subject to some exposure misclassifica-
tion, particularly among obese and underweight women. However, comparisons against exam-
iner-measured height and weight in this population suggest that women are accurate self-
reporters of their height and weight, and under-reporting for obese women is rarely >10%
[42].
Recall bias for the exposure could also be a potential problem in this study. Using an antibi-
otic three times a week for three months or more is an unusually long period of time for antibi-
otic usage. Although participants may be more likely to remember taking an antibiotic for this
length of time, it is also possible that women who recall taking antibiotics for an unusual length
of time, such as one month, may have incorrectly reported taking the antibiotic for the full
three months. Thus, the retrospective nature of this medication assessment is subject to some
exposure misclassification. Additionally, although long-term antibiotic use may be more likely
to impact the microbiome than short-term doses, antibiotic doses for one to two weeks are
much more common. Repeated dosings of smaller amounts do appear to bring about long-
lasting changes in gut microbiomes [11]. It is possible that many of the women that were clas-
sified as unexposed in the current study were actually exposed to multiple dosings of antibiot-
ics during the time periods of interest, but were considered unexposed because they did not
meet the criteria of taking antibiotics for 3 months or more at a time.
A final limitation is the external generalizability of the study. We only studied these associa-
tions in a female population that was mostly white. Therefore, we cannot draw conclusions
about the relevance of these findings to men, or to a population with a higher percentage of
minorities. Although we observed minimal confounding, and no effect modification by race/
ethnicity, residual confounding may be present. Minority participants in the Sister Study tend
to have higher incomes and to have competed more years of schooling than the general popu-
lation of minority women which could in turn affect factors related to both infection and
access to healthcare.
Study strengths include considering indication for use in analyses, using both retrospective
and prospective longitudinal data, and examination of this study question in an adult popula-
tion over a long period of time. The use of both retrospective and prospective data revealed a
few notable items. One, there were no associations between antibiotic use in the past 12
months and prospective weight change. It is possible that weight does not change immediately
after antibiotic exposure. Changes in satiety hormones and energy storage or harvest may not
stabilize until the relevant microbial communities stabilize in response to antibiotic exposure,
which may take several years. Second, associations for penicillins were consistent with both
retrospective and prospective data.
This potential antibiotic side effect should be further investigated, as public health impact
may be high. Antibiotic prescription rates are high; in 2011, healthcare providers prescribed
842 prescriptions per 1000 persons, and antibiotic prescriptions are prescribed incorrectly for
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between 38% to 60% of ambulatory visits [43, 44]. Perceptions in clinical communities about
harmful side effects of antibiotic use are generally limited to concerns about antibiotic resis-
tance, but the possible impact on the microbiota and associated ailments should be considered.
Long-term use of antibiotics is somewhat rare, and penicillins are used long-term for prophy-
lactic treatment of rheumatic fever, sickle cell disease, recurrent otitis media, endocarditis, sal-
monella infections, and certain types of Lyme disease. Although the benefits of antibiotics may
outweigh the possible side effects of weight gain in these clinical circumstances, patients should
be monitored for weight changes in response to judicious treatment.
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